Navigation Links
DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
Date:5/15/2009

PRINCETON, N.J., May 15 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, today announced its financial results for the first quarter of 2009.

DOR's revenues for the first quarter of 2009 were approximately $0.5 million compared to $0.7 million for the first quarter of 2008. The decreased revenues were primarily attributable to decreased research and development amounts drawn down from DOR's NIH Biodefense grants.

DOR's net loss for the first quarter of 2009 was approximately $2.1 million, or $0.01 per share, compared to $1.4 million, or $0.01 per share, for the first quarter of 2008. This increase was primarily attributed to increased spending of $968,996 in research and development in preparation for the initiation of the confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

Research and development expenses for the first quarter of 2009 were approximately $1.6 million, compared to $0.6 million for the first quarter of 2008. General and administrative expenses for the first quarter of 2009 were approximately $0.5 million, compared to $0.8 million for the first quarter of 2008.

"We are pleased with our progress thus far in 2009," stated Christopher J. Schaber, PhD, President and CEO of DOR. "We continue to work diligently towards the initiation of our confirmatory Phase 3 clinical trial of orBec(R) in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. We are also pleased with our new partnership with Sigma-Tau Pharmaceuticals. We now have an experienced partner in the HSC transplant arena, regulatory clarity with regard to the Phase 3 development of orBec(R), and a relatively clean capital structure. These new factors give us confidence that 2009 will be a year of substantial growth and progress for DOR."


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ,SARAH, ... yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma ... late 2016.   SARAH, a large French ... (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding ...
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... 03, 2015 Research and Markets ( ... "Gene Therapy Market, 2015 - 2025" report to ... 2015-2025" report provides an extensive study on the marketed ... been carried out in this field for over a ... available in Asian markets; one approved in the EU). ...
(Date:3/3/2015)... 03, 2015 BlueInGreen ... their international sales network. The business venture will ... to Canada’s Atlantic Provinces, exclusively through Resource Systems. ... one of Canada’s premiere manufacturing representative firms, hosting ... municipal water and wastewater markets. More information on ...
Breaking Biology Technology:Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2
... The California Department of Labor today awarded the ... grant to implement new workforce training programs for careers in ... collaborative effort including CleanTECH San Diego, BIOCOM, San Diego Regional ... San Diego Workforce Partnership, captured the grant through the California ...
... , GAITHERSBURG, Md. , June 29 ... the company has received two SBIR (Small Business Innovation ... National Institute of Allergy and Infectious Diseases ... a biopharmaceutical company founded in early 2007, is dedicated ...
... SAN DIEGO , June 29 ... two key commercialization milestones ahead of schedule. First, the ... manufacturability and commercial viability of a ,green, version of ... company confirmed the accelerated development time and reduced development ...
Cached Biology Technology:San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 2San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 3San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 4Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 2Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 3Sirnaomics Receives Two SBIR Grants from NIH for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 4Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 2Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 3Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 4
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... Science Foundation (NSF) totaling $3.4 million, the University of ... 300 teraflops to the TeraGrid,s total computational capability. ... 200 million additional service units, or CPU hours, per ... 800 million and benefitting the organization,s entire user community. ...
... a baseline for measuring and predicting the biological impact of ... Ohio biomedical informatics researcher are using Ohio Supercomputer Center, or ... the spill and chemicals and the distribution of various fish ... and even less about the interactions between this biota and ...
... American Association for Cancer Research (AACR), the world,s oldest ... the responsible conduct of human embryonic stem cell research ... National Institutes of Health (NIH) and expresses concern that ... funding for human embryonic stem cell research is a ...
Cached Biology News:NICS to add more than 300 Teraflops to the NSF’s computing capacity 2LSU expert teams with Ohio State researcher to track species affected by Gulf oil spill 2LSU expert teams with Ohio State researcher to track species affected by Gulf oil spill 3
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
fli-1...
Biology Products: